PD-1 blockade-resistant melanomaperitoneal tumorsadvanced melanomavidutolimodpembrolizumab
…onist, showed systemic monotherapy activity (9/40 responses) in PD-1 blockade-resistant melanoma. 1 In the randomized ECOG-ACRIN EA6194 trial in neoadjuvant mel…